

21 November 2022

Reference: Registration No. 64-R-0001, USDA Annual Report of Research Facility

FY 2022 APHIS Form 7023 Column E Explanation:

80 hamsters on SARS-CoV-2 vaccination, challenge, and therapeutic efficacy studies experienced unrelieved pain and/or distress subsequent to non-lethal virus challenge. The SR IACUC authorized the withholding of analgesics and anti-inflammatories based on the justification provided by the Study Director who stated that the animals which experienced SARS-CoV-2 related illnesses could not be treated with analgesics, as this would mask the clinical indicators of disease indicative of infection, could inadvertently enhance disease progression, and interfere with the viral pathogenesis, thus compromising the scientific integrity of the work.

Over the course of this is non-lethal SARS-CoV-2 infection hamsters exhibited no clinical signs of disease other than a 10-20% body weight loss post-challenge.



21 November 2022

Reference: Registration No. 64-R-0001, USDA Annual Report of Research Facility

FY 2022 APHIS Form 7023 Column E Explanation:

23 Cynomolgus macaques (*Macaca fascicularis*) and 3 African Green Monkeys (*Chlorocebus sabaeus*) on SARS-CoV-2 vaccination, challenge, and therapeutic efficacy studies experienced unrelieved pain and/or distress subsequent to nonlethal virus challenge. The SR IACUC authorized the withholding of analgesics and anti-inflammatories based on the justification provided by the Study Director who stated that the animals which experienced SARS-CoV-2 related illnesses could not be treated with analgesics, as this would mask the clinical indicators of disease indicative of infection, could inadvertently enhance disease progression, and interfere with the viral pathogenesis, thus compromising the scientific integrity of the work.

In this non-lethal model animals exhibited only moderate and transient signs of disease including reduced appetite, mild fever, and mildly decreased activity.



21 November 2022

Reference: Registration No. 64-R-0001, USDA Annual Report of Research Facility

FY 2022 APHIS Form 7023 Column E Explanation:

45 ferrets (*Mustela putorius furo*) used on an influenza challenge protocol developed clinical illness and are considered to have experienced some degree of unrelieved pain and/or distress secondary to influenza challenge. The withholding of anesthetics and analgesics was approved by the SR IACUC after justification by the Study Director who stated that alleviating clinical signs of disease alters the natural infection and immune response in animals thereby impacting data interpretation regarding the potential therapeutics at use in these projects.

Clinical signs of illness for animas on these studies included coughing, weight loss, respiratory distress, neurological signs, and moribundity.